Ovarian Cancer | Oncology Today with Dr Neil Love: The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer

1:09:32
 
Share
 

Manage episode 282732313 series 2513286
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Featuring an interview with Dr Shannon N Westin on the following topics:

  • Evolving role of PARP inhibition in the management of ovarian cancer (OC) (0:00)
  • Frequency and clinical significance of germline and somatic BRCA mutations and other genomic signatures that may predict benefit from PARP inhibition (3:46)
  • Pivotal Phase III trials of PARP inhibitors alone or in combination with bevacizumab as maintenance therapy for patients with newly diagnosed OC (8:51)
  • Approaches to overcoming PARP inhibitor resistance; PARP inhibitors in combination with immune checkpoint inhibitors (17:56)
  • Novel immune checkpoint inhibitor-based regimens under investigation in OC (25:15)
  • Case: A woman in her early 40s with newly diagnosed high-grade serous OC with a somatic BRCA mutation (28:03)
  • Integration of maintenance PARP inhibition alone or in combination with bevacizumab into the management of newly diagnosed OC (33:32)
  • Duration of PARP inhibitor maintenance therapy; clinical management of common treatment-associated side effects (38:19)
  • Case: A woman in her mid-60s with newly diagnosed Stage IV high-grade serous OC with evidence of genomic instability on her homologous recombination deficiency test (43:09)
  • Activity and tolerability of olaparib/bevacizumab as maintenance therapy (51:14)
  • Case: A woman in her early 50s with newly diagnosed Stage IV homologous recombination-proficient OC (58:53)

CME information and select publications

473 episodes